Research in cancer immunology at the Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University (JHU) has undergone a natural progression from basic laboratory studies of the host immune response to cancer to the clinical evaluation of immune-based cancer therapies. Many of these immune-based strategies to mobilize and augment the anti-tumor immune response were founded on the discoveries made by JHU investigators. Moreover, the application of immunotherapeutic strategies as an adjunct to cancer treatment across a wide range of malignancies and therapeutic settings has expanded dramatically over the past several years. The ability to carefully and reliably quantify the human immune response is critically important to assess the impact of any immunotherapeutic strategy. While there is great diversity in the therapeutic modalities being studied, most areas, in fact, overlap strongly in their techniques and approaches to immunological analysis. Modern immunological techniques for characterizing and quantifying human immune responses are complex, and it is difficult for individual investigators to assemble all the techniques that may be most appropriate for a particular project. The Human Immunology Core Laboratory (HICL) was established in 2005 to provide SKCCC investigators the capacity to reliably monitor and quantify human immune responses using state-of-the-art immunologic assays. Thus, the specific goals of this CORE are to: 1) Provide technical expertise and conduct immunological assays to monitor and characterize the human immune responses;2) Establish standard operating procedures and quality control measures for all immunological assays;3) Communicate its expertise and availability to SKCCC investigators;4) Provide technical support to SKCCC investigators seeking to identify and develop assays specific to their research objectives, and 5) Serve as a repository for key reagents and cell lines useful for the study of human immunology. Taken together, the HICL plays an important role in monitoring human immune responses that crosses many disciplines within the SKCCC and provides for the development of new therapeutic approaches to augment the anti-tumor immune response. Lay: The Human Immunology Core Laboratory identifies different subsets of lymphocytes that participate in the immune response to cancer and assesses their function and their ability to produce inflammatory cytokines that amplify the immune response. By tracking or monitoring the immune response, the Human Immunology Core Laboratory can assist investigators assess the impact or influence of their therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661014
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$70,761
Indirect Cost
$27,170
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bastos, Diogo A; Antonarakis, Emmanuel S (2018) AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Precis Cancer Med 1:
Stein-O'Brien, Genevieve; Kagohara, Luciane T; Li, Sijia et al. (2018) Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Med 10:37
Dean, Lorraine T; Montgomery, Madeline C; Raifman, Julia et al. (2018) The Affordability of Providing Sexually Transmitted Disease Services at a Safety-net Clinic. Am J Prev Med 54:552-558
Mondul, Alison M; Joshu, Corinne E; Barber, John R et al. (2018) Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study. Cancer Prev Res (Phila) 11:779-788
Lu, Dai-Yin; Yalçin, Hulya; Yalçin, Fatih et al. (2018) Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 121:1081-1089
Brundage, Michael; Blackford, Amanda; Tolbert, Elliott et al. (2018) Presenting comparative study PRO results to clinicians and researchers: beyond the eye of the beholder. Qual Life Res 27:75-90
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
El-Diwany, Ramy; Soliman, Mary; Sugawara, Sho et al. (2018) CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Sci Adv 4:eaat0843

Showing the most recent 10 out of 2393 publications